ArticleImmunity, inflammation and disease2016
IL-6-specific autoantibodies among APECED and thymoma patients.
Article in Immunity, inflammation and disease, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Autoantibodies against type I interferons in COVID-19 infection: A systematic review and meta-analysis.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2023Pooled it
- Article
- Dysregulated IL-6 pathway activity in idiopathic inflammatory myopathies.Arthritis research & therapy · 2026Article
- Rare pediatric Saccharomyces cerevisiae fungemia with neutralizing anti-IL-23 autoantibodies: a case report.BMC pediatrics · 2026Article
- Good's Syndrome Mirrors a Combined Immunodeficiency with Anti-Cytokine Antibodies in the Total Absence of B Cells.Journal of clinical immunology · 2026Article
- Common connective tissue disorder and anti-cytokine autoantibodies are enriched in idiopathic multicentric castleman disease patients.Frontiers in immunology · 2025Article
- Non-neutralizing anti-type I interferon autoantibodies could increase thrombotic risk in critical COVID-19 patients.Frontiers in immunology · 2025Article
- Autoimmunity against cytokines: Double strike in autoimmune disease, a historical perspectiveBiomedica : revista del Instituto Nacional de Salud · 2024Review
- The ouroboros of autoimmunity.Nature immunology · 2024Review
- Anti-Interleukin-23 Autoantibodies in Adult-Onset Immunodeficiency.The New England journal of medicine · 2024Article
- Anti-cytokine autoantibodies: mechanistic insights and disease associations.Nature reviews. Immunology · 2024Review
- Novel Insights into the Autoimmunity from the Genetic Approach of the Human Disease.Advances in experimental medicine and biology · 2024Article
- Insights from a Case of Good's Syndrome (Immunodeficiency with Thymoma).Biomedicines · 2023Article
- Autoantibodies to Interferons in Infectious Diseases.Viruses · 2023Review
- Advancing Luciferase-Based Antibody Immunoassays to Next-Generation Mix and Read Testing.Biosensors · 2023Review
- Inactive disease in patients with lupus is linked to autoantibodies to type I interferons that normalize blood IFNα and B cell subsets.Cell reports. Medicine · 2023Article
- Anticytokine autoantibodies: Autoimmunity trespassing on antimicrobial immunity.The Journal of allergy and clinical immunology · 2022Review
- The Role of IL-17-Producing Cells in Cutaneous Fungal Infections.International journal of molecular sciences · 2021Review
- The Role of GM-CSF Autoantibodies in Infection and Autoimmune Pulmonary Alveolar Proteinosis: A Concise Review.Frontiers in immunology · 2021Review
- Autoantibodies against cytokines: phenocopies of primary immunodeficiencies?Human genetics · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 4 countries.
Funding
Abstract
introductionBoth autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) and the rare thymoma patients with chronic mucocutaneous candidiasis (CMC) have neutralizing autoantibodies to Th17 cytokines and significant defects in production of IL-22 and IL-17F by their T cells. The cause of these defects is unknown. We hypothesized that they might result from autoimmunity against upstream cytokines normally responsible for generating and maintaining Th17 cells.
methodsLuciferase immunoprecipitation (LIPS) was used to screen for autoantibodies to IL-6, IL-1β, TGF-β3, IL-21, and IL-23 in patients with APECED or thymoma. We used Western blotting to assess the conformation-dependence of the IL-6 autoantibodies and flow cytometric analysis of intracellular phospho-STAT3 induction to assess IL-6-neutralizing capacity in IgGs isolated from patient and control sera. We also used Luminex xMAP to measure serum cytokine levels.
resultsWe found autoantibodies binding to conformational epitopes of IL-6 in 19.5% of 41 patients with APECED and 12.5% of 104 with thymoma-especially in those with long disease durations. The autoantibodies were predominantly of IgG1 subclass and failed to neutralize IL-6 activity. Notably, serum levels of the IL-6 and IL-17A cytokines were higher in anti-IL-6 seropositive than-negative APECED patients or healthy controls. We also detected autoantibody binding to IL-23 in 27.9% of thymoma patients, resulting from cross-recognition through the p40 subunit it shares with IL-12.
conclusionsIL-6 and IL-17A elevation in these seropositive patients suggests that antibody-binding may protect IL-6 from degradation and prolong its half-life in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.